Read + Share

Amedeo Smart

Independent Medical Education


Read + Share

Vora SM, Boyd S, Denny N, Jackson E, et al. Expanded eligibility for emerging therapies in sickle cell disease in the UK - crizanlizumab and voxelotor. Br J Haematol 2022;197:502-504.
PMID: 35189668


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016